These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 15083284)

  • 1. Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis.
    Dalton CM; Miszkiel KA; Barker GJ; MacManus DG; Pepple TI; Panzara M; Yang M; Hulme A; O'Connor P; Miller DH
    J Neurol; 2004 Apr; 251(4):407-13. PubMed ID: 15083284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A study of subtle blood brain barrier disruption in a placebo-controlled trial of natalizumab in relapsing remitting multiple sclerosis.
    Soon D; Altmann DR; Fernando KT; Giovannoni G; Barkhof F; Polman CH; O'Connor P; Gray B; Panzara M; Miller DH
    J Neurol; 2007 Mar; 254(3):306-14. PubMed ID: 17277910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.
    Miller DH; Soon D; Fernando KT; MacManus DG; Barker GJ; Yousry TA; Fisher E; O'Connor PW; Phillips JT; Polman CH; Kappos L; Hutchinson M; Havrdova E; Lublin FD; Giovannoni G; Wajgt A; Rudick R; Lynn F; Panzara MA; Sandrock AW;
    Neurology; 2007 Apr; 68(17):1390-401. PubMed ID: 17452584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis.
    Radue EW; Sprenger T; Vollmer T; Giovannoni G; Gold R; Havrdova E; Selmaj K; Stefoski D; You X; Elkins J
    Eur J Neurol; 2016 Feb; 23(2):412-5. PubMed ID: 26806217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis.
    O'Connor P; Miller D; Riester K; Yang M; Panzara M; Dalton C; Miszkiel K; Khan O; Rice G; Sheremata W;
    Mult Scler; 2005 Oct; 11(5):568-72. PubMed ID: 16193895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A controlled trial of natalizumab for relapsing multiple sclerosis.
    Miller DH; Khan OA; Sheremata WA; Blumhardt LD; Rice GP; Libonati MA; Willmer-Hulme AJ; Dalton CM; Miszkiel KA; O'Connor PW;
    N Engl J Med; 2003 Jan; 348(1):15-23. PubMed ID: 12510038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects.
    O'Connor PW; Goodman A; Willmer-Hulme AJ; Libonati MA; Metz L; Murray RS; Sheremata WA; Vollmer TL; Stone LA;
    Neurology; 2004 Jun; 62(11):2038-43. PubMed ID: 15184611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis.
    MacManus DG; Miller DH; Kappos L; Gold R; Havrdova E; Limmroth V; Polman CH; Schmierer K; Yousry TA; Eraksoy M; Meluzinova E; Dufek M; Yang M; O'Neill GN; Dawson K
    J Neurol; 2011 Mar; 258(3):449-56. PubMed ID: 20963434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study.
    Havrdova E; Galetta S; Hutchinson M; Stefoski D; Bates D; Polman CH; O'Connor PW; Giovannoni G; Phillips JT; Lublin FD; Pace A; Kim R; Hyde R
    Lancet Neurol; 2009 Mar; 8(3):254-60. PubMed ID: 19201654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.
    Hutchinson M; Kappos L; Calabresi PA; Confavreux C; Giovannoni G; Galetta SL; Havrdova E; Lublin FD; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Rudick RA; Stuart WH; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA;
    J Neurol; 2009 Mar; 256(3):405-15. PubMed ID: 19308305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis.
    Zivadinov R; Dwyer MG; Ramasamy DP; Davis MD; Steinerman JR; Khan O
    J Neuroimaging; 2015; 25(6):989-95. PubMed ID: 26394270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.
    Radue EW; Stuart WH; Calabresi PA; Confavreux C; Galetta SL; Rudick RA; Lublin FD; Weinstock-Guttman B; Wynn DR; Fisher E; Papadopoulou A; Lynn F; Panzara MA; Sandrock AW;
    J Neurol Sci; 2010 May; 292(1-2):28-35. PubMed ID: 20236661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of disease-modifying therapies on MRI outcomes in patients with relapsing -remitting multiple sclerosis: A systematic review and network meta-analysis.
    Bose D; Ravi R; Maurya M; Pushparajan L; Konwar M
    Mult Scler Relat Disord; 2022 May; 61():103760. PubMed ID: 35381534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
    Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V
    Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis.
    McCormack PL
    Drugs; 2013 Sep; 73(13):1463-81. PubMed ID: 23912625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natalizumab prevents the accumulation of cortical lesions in relapsing remitting multiple sclerosis: a preliminary report.
    Rinaldi F; Calabrese M; Seppi D; Puthenparampil M; Perini P; Gallo P
    Neurol Sci; 2011 Jan; 31 Suppl 3():317-20. PubMed ID: 20535514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
    Polman CH; O'Connor PW; Havrdova E; Hutchinson M; Kappos L; Miller DH; Phillips JT; Lublin FD; Giovannoni G; Wajgt A; Toal M; Lynn F; Panzara MA; Sandrock AW;
    N Engl J Med; 2006 Mar; 354(9):899-910. PubMed ID: 16510744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natalizumab versus fingolimod for patients with active relapsing-remitting multiple sclerosis: results from REVEAL, a prospective, randomised head-to-head study.
    Butzkueven H; Licata S; Jeffery D; Arnold DL; Filippi M; Geurts JJ; Santra S; Campbell N; Ho PR;
    BMJ Open; 2020 Oct; 10(10):e038861. PubMed ID: 33082194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial.
    Miller DH; Weber T; Grove R; Wardell C; Horrigan J; Graff O; Atkinson G; Dua P; Yousry T; Macmanus D; Montalban X
    Lancet Neurol; 2012 Feb; 11(2):131-9. PubMed ID: 22226929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study.
    Arnold DL; Gold R; Kappos L; Bar-Or A; Giovannoni G; Selmaj K; Yang M; Zhang R; Stephan M; Sheikh SI; Dawson KT
    J Neurol; 2014 Sep; 261(9):1794-802. PubMed ID: 24989666
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.